Beyond the Endpoint

Kick off 2026 with hosts Manesh Patel and Emily O'Brien as they evaluate last year's most discussed health stories and wellness trends, cannabis reclassification, and a shingles vaccine-dementia study.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-9-beyond-headlines

Kick off 2026 with hosts Manesh Patel and Emily O'Brien as they evaluate last year's most discussed health stories and wellness trends, cannabis reclassification, and a shingles vaccine-dementia study.

Hosts Manesh Patel and Emily O'Brien share their amusing and inspiring personal and professional trajectories, exploring how mentors shaped their paths in clinical research, why asking unconventional questions matters, and how success rarely follows a straight line.

🎙️ Listen now for the full conversation: https://dcri.org/blog/s2-ep-8-behind-voices-get-know-emily-manesh

Hosts Emily O’Brien and Manesh Patel sit down with Dr. Ajay Kohli and Dr. Julius Wilder for a dual-perspective conversation on colorectal cancer, where they discuss personal experiences, the importance of early detection, screening disparities, and how equitable access to care saves lives.

🔗Access resources related to this episode: https://dcri.org/blog/s2-ep-7-provider-patient-dual-perspective-colorectal-cancer

Recorded at the 2025 American Heart Association Scientific Sessions, hosts Manesh Patel and Emily O'Brien discuss late-breaking cardiovascular research, including gene-editing therapy for cholesterol, AFib management strategies, and, for coffee lovers, the DECAF trial's findings on caffeine and heart rhythm.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-6-beyond-headlines

#AHA25 #beyondtheendpoint #cardiology #podcast #hearthealth #clinicalresearch

Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-5-connecting-dots-broader-applications-glp-1s-and-where-were-headed-next

In this second episode of our obesity series, preventive cardiologist Neha Pagidipati sheds light on the discovery, impact, and uses of GLP-1s, like Ozempic and Mounjaro. Learn about the impact these medications are having on diabetes, heart disease, and weight management.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-4-obesity-glp-1s-and-evidence-what-data-tells-us

In the first of a three-part series on obesity and GLP-1 medications, our guest Jennifer Norris shares the evolving landscape of obesity treatment. The conversation addresses common misconceptions and examines how GLP-1 medications, such as Ozempic, have transformed care alongside surgery and lifestyle interventions.

The "Beyond the Headlines" series returns with summer healthcare and research news. Hosts Manesh Patel and Emily O'Brien discuss misconceptions about research funding, a Danish study on vaccine safety, the potential impacts of poor sleep, and how AI tools are transforming medical practice and training.

Tags: #medicalnews #healthnews #research #clinicalresearch

Ushering in the second season of Beyond the Endpoint, Lauren Franz, MBChB, MPH, interim director of the Duke Center for Autism and Brain Development, joins Manesh Patel and Emily O'Brien for an in-depth conversation about autism research, care, and community. Franz explains what autism is as a neurodevelopmental spectrum condition and how our understanding of it has evolved significantly over the last decade. The discussion examines the intricate interplay between genetic and environmental factors that may contribute to the development of autism, and explores current intervention approaches. The hosts and guest also discuss the groundbreaking research at Duke University that employs artificial intelligence to analyze medical records for earlier detection of autism. This approach could help shorten the time between when autism can be diagnosed and when it is typically identified. Throughout the episode, Franz stresses the importance of involving the autism community in research and decision-making processes.